Summary. The inflammatory cytokine interferon gamma (IFNg) can cause cell cycle arrest and apoptosis in the hepatocyte. Primarily these processes are protective but in chronic liver disease oncogenic mutations may prosper. IFNg signalling is discussed showing how p53 is induced to cause cell cycle arrest. While caspases are are known to be responsible for IFNg induced apoptosis, how they are activated is unclear. Potential mechanisms are reviewed.

Interferon gamma (IFNgamma) is an important mediator of inflammatory liver damage as part of a complex cytokine network. In vitro, IFNgamma induces hepatocyte apoptosis. We hypothesized that the hepatocyte response to IFN signalling is context-dependent, and that specific growth factors, via phosphatidylinositol 3 kinase (PI(3)K) and protein kinase B/Akt signalling pathways, confer a cytoprotective effect. We established an in vitro model of IFNgamma-mediated primary hepatocyte injury. We show that epidermal growth factor (EGF) and hepatocyte growth factor (HGF) attenuate the IFNgamma-induced hepatocyte apoptosis. IRF-1, but not p53, is required for IFNgamma-mediated apoptosis. The loss of p21(waf-1) not only sensitizes the hepatocyte to IFNgamma-mediated injury but is required for survival factor mediated cytoprotection. We show that the PI(3)K inhibitor, LY294002, partially inhibits the apoptotic response of the hepatocyte to IFNgamma. In summary, we present evidence that a component of pro-apoptotic IFNgamma signalling in the primary hepatocyte occurs via the PI(3)K pathway. We show that the hepatocyte response to IFNgamma is modulated by external survival factors and that this survival signalling requires p21(waf-1).

Interferon-gamma (IFNgamma) is a central component of the complex cytokine and inflammatory response that contributes to liver cell injury in hepatitis. We report that in the primary hepatocyte IFNgamma synergizes with the mechanistically distinct apoptotic stimuli CD95, tumour necrosis factor-alpha (TNFalpha) and UV-irradiation. For the first time in primary hepatocytes, we show that IFNgamma-mediated apoptotic signalling requires the cell surface interaction of CD95 and its ligand, and we demonstrate that IFNgamma induces soluble CD95 ligand release from hepatocyte monolayers. Utilizing c-myc phosphorothioate antisense fragments, we suppresses hepatocyte apoptosis induced by IFNgamma. In summary, we identify apoptotic pathways that contribute to IFNgamma-mediated cell death. The hepatocellular response to IFNgamma signalling can be modulated by cytokines and by the interruption of CD95 interaction with its ligand. We present evidence to suggest that c-myc contributes to IFNgamma signalling.